New AbbVie hepatitis C regimen shows high cure rates: studies

Reuters Health Information: New AbbVie hepatitis C regimen shows high cure rates: studies

New AbbVie hepatitis C regimen shows high cure rates: studies

Last Updated: 2016-04-18

By Bill Berkrot

(Reuters) - An experimental once-daily combination hepatitis C treatment being developed by AbbVie demonstrated very high cure rates across a wide range of disease genotypes, according to data presented on Saturday, likely giving the company a more competitive product if approved.

Cure rates of 97% to 100% over either eight or 12 weeks of treatment were achieved in the clinical trials with the one pill, once-a-day combination of ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor.

The combination would provide greater convenience for a wider variety of patients than AbbVie's Viekira Pak, improving chances of making inroads into the market domination currently enjoyed by Gilead Sciences.

Viekira Pak, which is approved for genotype 1, the most common form of the serious liver disease in the United States, consists of four drugs and involves taking three pills in the morning and one in the evening. It currently has only about 5% of the market, with Gilead owning about 90%.

Another AbbVie product treats genotype 4, which is most common in Egypt and other parts of Africa.

The new one pill combination proved effective across the spectrum of genotypes 1-6 in the midstage studies presented at The International Liver Congress 2016 in Barcelona, Spain.

In patients without cirrhosis who were not helped by an older regimen, 97% of those with genotype 1 and 98% of those with genotype 2 had no detectable hepatitis C virus in the blood 12 weeks after completing eight weeks of therapy, which is considered cured.

Patients with genotype 3 and no cirrhosis receiving treatment for the first time had a 97% cure rate with eight weeks of therapy.

Cure rates of 100% were achieved with 12 weeks of treatment in genotype 3 patients with cirrhosis, and in non-cirrhotic patients with genotypes 4, 5, and 6.

"These new data show us the potential of ABT-493 and ABT-530 in genotype 3 patients new to therapy even with the added complication of compensated cirrhosis," Dr. Paul Kwo, one of the lead investigators and professor of medicine at the Indiana University School of Medicine, said in a statement.

The most common side effects were fatigue, headache, nausea, and diarrhea, the company reported.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.